Src
Src family kinase (SFK) is a family of non-receptor tyrosine kinases including nine members: Src, Yes, Fyn, and Fgr, forming the SrcA subfamily, Lck, Hck, Blk, and Lyn in the SrcB subfamily, and Frk in its own subfamily. In immune cells, Src-family kinases (SFKs) have been implicated as critical regulators of a large number of intracellular signaling pathways. Src-family kinases (SFKs) occupy a proximal position in numerous signaling transduction cascades including those emanating from the T and B cell antigen receptors, Fc receptors, growth factor receptors, cytokine receptors, and integrins. In addition to these positive regulatory roles, Src-family kinases (SFKs) can also function as negative regulators of cellular signaling by phosphorylating immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on inhibitory receptors, resulting in recruitment and activation of inhibitory molecules such as the phosphatases SHP-1 and SH2 containing 5′ inositol phosphatase (SHIP-1).
Src Isoform Specific Products
All Product Categories
-
Src Related Products (346)
Related Products (346)
-
Antibodies (15)
-
Src Isoform Comparison
-
N-Acetyl-O-phosphono-Tyr-Glu dipentylamide
0 ImagesCat. No.: HY-108487CAS No.: 190078-50-3Synonyms: Ac-Tyr-Glu-N(n-C5H11)2N-Acetyl-O-phosphono-Tyr-Glu dipentylamide (Ac-Tyr-Glu-N(n-C5H11)2), a dipeptide, is a pp60c-src SH2 domain inhibitor. N-Acetyl-O-phosphono-Tyr-Glu dipentylamide can be used for cancer research.
-
AP-24567
0 ImagesCat. No.: HY-125142CAS No.: 943319-87-7AP-24567 is a Ligands for Target Protein for PROTAC, which can be used for the synthesis of SB1-G-187 (HY-137342).
-
EGFR/c-SRC-IN-1
0 ImagesCat. No.: HY-184274EGFR/c-SRC-IN-1 is a blood-brain barrier-impermeable, ATP-competitive dual-target inhibitor of EGFR/c-SRC, with an IC50 of 0.05 μM against EGFR and an IC50 of 0.07 μM against c-SRC. EGFR/c-SRC-IN-1 shows selectivity toward ABL-2 and VEGFR-2 kinases. EGFR/c-SRC-IN-1 triggers endogenous apoptosis by upregulating p53 and Bax, downregulating Bcl-2, and altering the Bax/Bcl-2 ratio. EGFR/c-SRC-IN-1 can be used in the research of non-small cell lung cancer, hepatocellular carcinoma, and triple-negative breast cancer.
-
Birelentinib
0 ImagesCat. No.: HY-160167CAS No.: 2662512-15-2Synonyms: DZD8586Birelentinib (DZD8586) is an orally effective, selective, non-covalent inhibitor targeting LYN tyrosine kinase and BTK tyrosine kinase, capable of penetrating the blood-brain barrier. Birelentinib exhibits concentration-dependent antiproliferative effects in RI-1 cells and diffuse large B-cell lymphoma (DLBCL) cell lines carrying BTK resistance mutations (such as C481X, V416L, etc.). Birelentinib blocks both BTK-dependent and independent signaling of the B-cell receptor (BCR), thereby inhibiting tumor cell proliferation and inducing cell death. Birelentinib can be used in research to overcome resistance to existing covalent and non-covalent BTK inhibitors in B-cell non-Hodgkin lymphoma (B-NHL).
-
P60v-src(137-157)
0 ImagesCat. No.: HY-P2372CAS No.: 131023-24-0P60v-src(137-157) is a synthetic peptide that inhibits the tyrosine kinase activity of p60v-src (IC50: 7.5 μM).
-
HPK1-IN-61
0 ImagesCat. No.: HY-177272CAS No.: 875638-86-1HPK1-IN-61 (Compound 1) is an inhibitor of hematopoietic progenitor kinase 1 (HPK1) (Ki = 0.4 nM) and an inhibitor of Abl (IC50 < 0.51 nM). HPK1-IN-61 also shows inhibitory activity against LCK with an IC50 of 24 nM.
-
Tesevatinib tosylate
0 ImagesCat. No.: HY-13314ACAS No.: 1000599-06-3Synonyms: XL-647 tosylate; EXEL-7647 tosylate; KD-019tosylateTesevatinib (XL-647) tosylate is an orally available, blood-brain barrier-penetrant inhibitor of the epidermal growth factor receptor (EGFR). Tesevatinib tosylate significantly reduces cellular viability, with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Tesevatinib tosylate also inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM). Tesevatinib tosylate can inhibit tumor proliferation and exhibits antitumor activity.
-
Lysoganglioside-GM1 ammonium
0 ImagesCat. No.: HY-131931ASynonyms: LysoGM1 ammoniumLysoganglioside-GM1 (LysoGM1) ammonium is a derivative of Monosialoganglioside GM1, which lacks a fatty acid. Lysoganglioside-GM1 ammonium is also an inhibitor of GM1 aggregation. Lysoganglioside-GM1 ammonium can inhibit the activation of Lyn and laminin-1-mediated neurite outgrowth. Lysoganglioside-GM1 ammonium can be used in the research of nervous system diseases.
-
Hck-IN-3
0 ImagesCat. No.: HY-178950CAS No.: 3115216-60-6Hck-IN-3 (compound 2D) is an orally effective inhibitor targeting HCK (KD = 3.92 μM). Hck-IN-3 can inhibit the release of NO. Hck-IN-3 has an IC50 of 6.52 μM in RAW264.7 cells. Hck-IN-3 can inhibit the release of TNF-α, IL-6, and IL-1β in a concentration dependent manner. Hck-IN-3 downregulates the protein expression of NLRP3, ASC, pro-caspase-1, and pro-IL-1β in a concentration dependent manner. Hck-IN-3 can be used for research on acute non traumatic inflammatory conditions.
-
p60c-src substrate II, phosphorylated
0 ImagesCat. No.: HY-P3771CAS No.: 284660-72-6p60c-src substrate II，phosphorylated is a pentapeptide. p60c-src substrate II，phosphorylated is a p60c-src substrate II phosphorylated polypeptide. Protein phosphorylation is an important post-translationmodification of protein that is indispensible in biological regulations.
-
Antiallergic agent-1
0 ImagesCat. No.: HY-115723CAS No.: 2839159-12-3Antiallergic agent-1, a Src-family kinase inhibitor, may serve as a new valuable lead compound for future antiallergic agent discovery. Antiallergic agent-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
MLS-2384 free base
0 ImagesCat. No.: HY-125718CAS No.: 1067884-45-0MLS-2384 free base is a dual JAK/Src kinase inhibitor. MLS-2384 free base downregulates STAT3 downstream proteins c-Myc and Mcl-1. MLS-2384 free base induces Apoptosis. MLS-2384 free base exhibits anticancer activity against prostate cancer, breast cancer, skin cancer, ovarian cancer, lung cancer, and liver cancer.
-
PDD-87
0 ImagesCat. No.: HY-183103CAS No.: 2222129-13-5PDD-87 is an orally active, blood-brain barrier permeable kinase inhibitor, with IC50 values ranging from 0.07 nM to 0.72 nM against ABL, SRC family, BTK kinases and their key mutants. PDD-87 induces antiproliferative effects in leukemia and lymphoma cells, and inhibits tumor growth in mouse xenograft models. PDD-87 can be used for the research of leukemia and lymphoma.
-
Ac-PPPHPHARIK-NH2
0 ImagesCat. No.: HY-P2413CAS No.: 957791-38-7Ac-PPPHPHARIK-NH2 (compound S1) is a compound that inhibits the interaction between androgen receptor and Src. It can inhibit the binding of androgen or estrogen-induced receptor and Src in cancer cells, as well as the activation of related signaling pathways, and can also inhibit cell cycle progression and tumor growth.
-
LCB 03-0110
0 ImagesCat. No.: HY-110367ACAS No.: 1228102-01-9LCB 03-0110, a thienopyridine derivative, is a potent pan-discoidin domain receptor/c-Src family tyrosine kinase inhibitor. LCB 03-0110 suppresses scar formation by inhibiting fibroblast and macrophage activation.
-
PP487
0 ImagesCat. No.: HY-15268CAS No.: 1092787-12-6
